Obituary: India loses R&D champion as Dr Anji Reddy dies aged 72
This article was originally published in Scrip
"I hate the term Third World country and maybe if we produce 30 Merck-like companies in India then this nomenclature will be dropped," Dr Anji Reddy, founder and chairman of Dr Reddy's Laboratories (DRL), once said at a lecture in Mumbai. This was quite characteristic of the man who always believed Indian firms and R&D are world class and that India would one day emerge as a nucleus of drug discovery.
You may also be interested in...
The past decade witnessed a bout of pharma 'shock and awe' events in India, some of which still reverberate across the industry. The period also marked the death of doyens of the Indian pharmaceutical sector, including the founders of Dr Reddy’s and Lupin.
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market.